Research report · Public share

Innovent Biologics

HK · 01801 · 2026-10-22 · Full research
Cautiously bullish
Investment opportunity**Modestly positive risk-reward over the next 18 months; not deeply undervalued:** 2026H1 product revenue +56.7% and the registration milestones of three globalized assets form the fundamental base. At HKD 89.1, the current price trades at a ~10.4% discount to the SOTP mid-point
How was this report? Leave anonymous feedback.
This report was generated automatically by Loyan AI. For research reference only — not investment advice.
Want a research assistant that never forgets and challenges its own views?
Sign in to add this research to your library, or register for free to get started.
Sign in / register free